Laman Utama207940 • KRX
add
Samsung Biologics Co Ltd
Tutup sebelumnya
₩1,766,000.00
Julat hari
₩1,741,000.00 - ₩1,778,000.00
Julat tahun
₩982,000.00 - ₩1,987,000.00
Permodalan pasaran
82.31T KRW
Bilangan Purata
60.28K
Nisbah P/E
51.57
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (KRW) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | 1.29T | 2.35% |
Perbelanjaan pengendalian | 144.00B | -56.91% |
Pendapatan bersih | 510.00B | 58.63% |
Margin untung bersih | 39.66 | 54.98% |
Pendapatan bagi setiap syer | 5.72K | -17.60% |
EBITDA | — | — |
Kadar cukai berkesan | 21.22% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (KRW) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.46T | 9.37% |
Jumlah aset | 11.06T | -36.20% |
Jumlah liabiliti | 3.61T | -43.87% |
Jumlah ekuiti | 7.45T | — |
Syer tertunggak | 46.29J | — |
Harga kepada buku | 10.97 | — |
Pulangan pada aset | — | — |
Pulangan pada modal | — | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (KRW) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 510.00B | 58.63% |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Diasaskan
2011
Tapak web
Pekerja
4,770
